New drug combo aims to stop aggressive breast cancer from coming back

NCT ID NCT05949021

Summary

This study is testing a combination of two chemotherapy drugs (liposomal doxorubicin and carboplatin) given after surgery for early-stage triple-negative breast cancer (TNBC). The main goal is to see if this treatment can lower the chance of the cancer returning. Researchers will also closely monitor side effects and test a new blood marker (ctDNA) to see if it can predict treatment success.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER, TNBC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • RWJBarnabas Health - Community Medical Center

    Toms River, New Jersey, 08755, United States

  • RWJBarnabas Health - Monmouth Medical Center Southern Campus

    Lakewood, New Jersey, 08701, United States

  • RWJBarnabas Health - Newark Beth Israel Medical Center

    Newark, New Jersey, 07112, United States

  • RWJBarnabas Health - Robert Wood Johnson University Hospital

    New Brunswick, New Jersey, 08903, United States

  • RWJBarnabas Health - Trinitas hospital and Comprehensive Center

    Elizabeth, New Jersey, 08755, United States

  • RWJBarnabas Health Jersey City Medical Center

    Jersey City, New Jersey, 07302, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • University Hospital-Newark

    Newark, New Jersey, 07112, United States

Conditions

Explore the condition pages connected to this study.